Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) CEO John David Finley sold 146,798 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total transaction of $303,871.86. Following the sale, the chief executive officer directly owned 217,555 shares of the company’s stock, valued at $450,338.85. This represents a 40.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Palisade Bio Stock Performance
Palisade Bio stock opened at $2.05 on Thursday. The firm has a market cap of $355.84 million, a price-to-earnings ratio of -2.03 and a beta of 1.50. Palisade Bio, Inc. has a 52-week low of $0.53 and a 52-week high of $2.86. The firm has a 50 day moving average price of $1.92 and a two-hundred day moving average price of $1.92.
Palisade Bio (NASDAQ:PALI – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, equities research analysts predict that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.
Institutional Investors Weigh In On Palisade Bio
More Palisade Bio News
Here are the key news stories impacting Palisade Bio this week:
- Positive Sentiment: Director Robert Jr. Baltera bought 30,000 shares at about $2.03 per share, following earlier purchases of 20,000 shares and 10,000 shares at $1.98. Repeated insider buying can signal confidence in Palisade Bio’s outlook. SEC filing
- Positive Sentiment: Analysts remain broadly constructive on Palisade Bio, with recent ratings including a “strong-buy” upgrade and multiple buy ratings, plus a consensus price target well above the current trading range. MarketBeat PALI page
- Neutral Sentiment: CEO John David Finley sold 146,798 shares, but the filing says the transaction was to cover tax withholding obligations tied to vesting equity awards, which makes the sale less concerning than a discretionary insider exit. SEC filing
- Neutral Sentiment: Insider Mitchell Lawrence Jones also sold shares for the same tax-withholding reason, adding to the day’s mixed insider activity. SEC filing
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on PALI. Wolfe Research initiated coverage on Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target for the company. Oppenheimer set a $7.00 price objective on Palisade Bio in a research note on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Sunday. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Finally, Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.83.
View Our Latest Research Report on Palisade Bio
About Palisade Bio
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
Featured Articles
- Five stocks we like better than Palisade Bio
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
